J07BC01 - Hepatitis B, Purified Antigen

Probably not porphyrinogenic

Rationale

Based on the pharmacokinetics of the hepatitis B, purified antigen vaccine, there are no conceivable porphyrinogenic effects.

Chemical description

Hepatitis B surface antigen

Therapeutic characteristics

The vaccine is indicated for the active immunization of adults, children and infants against hepatitis B. It is administered by intramuscular injections according to a three or four dose schedule.

Metabolism and pharmacokinetics

The hepatitis vaccine is not metabolized by the cytochrome P450 system.

IPNet drug reports

Uneventful use reported in 1 patient with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes J07B / J07BC or go back.

References

#	Citation details	PubMed ID
Government bodies
1.	Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
Summary of Product Characteristics
2.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). HBVAXPRO. (Last edition: March 2014).

Citation details

PubMed ID

Government bodies

Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). HBVAXPRO. (Last edition: March 2014).

Tradenames

Show more details and information about the listed tradenames